Skip to main content

Table 6 GO categories of SUMO targeting genes with no expression changes during KSHV reactivation

From: The chromatin modification by SUMO-2/3 but not SUMO-1 prevents the epigenetic activation of key immune-related genes during Kaposi’s sarcoma associated herpesvirus reactivation

    SUMO-2/3 12 h SUMO-2/3 enriched at 12 hr
    All genes Gene expression no change Gene expression no change
  Pathway category Genes in category Genes identified p-value Genes identified p-value Genes identified p-value
Pathogen-influenced signaling Virus entry via endocytic pathways 99 31 1.41E-03 28 3.24E-03 20 5.13E-03
Cellular immune response Antigen Presentation pathway 40 14 1.26E-02 12 3.63E-02 9 3.24E-02
  CD40 signaling 70 23 2.82E-03 21 4.79E-03 14 1.91E-02
  HMGB1 signaling 99 25 9.33E-02 24 6.46E-02 16 1.03E-01
  IL-10 signaling 78 19 9.55E-02 16 2.07E-01 11 2.10E-01
  IL-15 signaling 67 20 1.86E-02 19 1.55E-02 16 2.34E-03
  IL-3 signaling 74 23 1.41E-02 22 1.02E-02 14 4.90E-02
  IL-8 signaling 205 48 4.68E-02 44 6.92E-02 27 2.14E-01
  NF-κB activation by viruses 82 23 2.00E-02 21 3.16E-02 15 3.39E-02
  p38 MAPK signaling 117 26 3.80E-01 24 3.88E-01 16 3.79E-01
  Toll-like receptor signaling 62 17 5.75E-02 15 9.55E-02 11 7.76E-02
Cytokine signaling IL-17A signaling in airway cells 72 21 1.35E-02 2 8.51E-02 11 1.58E-01
  Prolactin signaling 80 22 3.72E-02 22 1.45E-02 17 6.46E-03
Cancer Glioma signaling 112 29 1.55E-02 27 1.62E-02 19 2.14E-02
  p53 signaling 96 32 1.48E-03 27 1.23E-02 20 8.51E-03
  Small cell lung cancer signaling 89 27 6.03E-04 26 3.63E-04 20 2.57E-04
Cellular growth, proliferation and development Cleavage and polyadenylation of pre-mRNA 12 5 8.32E-02 5 6.03E-02 4 5.01E-02
  EGF signaling 62 21 2.88E-03 20 2.34E-03 13 1.66E-02
  FAK signaling 101 27 1.32E-02 26 9.33E-03 17 3.47E-02
  JAK/Stat signaling 70 26 5.37E-04 24 8.71E-04 20 1.07E-04
  Oncostatin M signaling 35 12 3.55E-02 11 4.47E-02 8 5.01E-02
  PDGF signaling 85 25 1.07E-02 24 6.92E-03 18 5.01E-03
  Thrombopoietin signaling 63 17 4.90E-02 17 2.29E-02 12 3.31E-02
  VEGF signaling 103 25 7.59E-02 25 3.47E-02 16 9.55E-02
Cell cycle regulation Cyclins and cell cycle regulation 89 24 2.75E-02 23 2.19E-02 13 1.80E-01
  GADD45 signaling 22 9 8.51E-03 8 2.40E-02 4 2.26E-01
  Mitotic roles of polo-like kinase 70 18 1.39E-01 18 7.24E-02 9 4.44E-01
Growth Ffactor signaling ErbB2-ErbB3 signaling 60 19 1.82E-02 19 7.08E-03 15 3.02E-03
Apoptosis April mediated signaling 43 13 3.72E-02 11 9.12E-02 6 3.24E-01
  Aryl hydrocarbon receptor signaling 161 40 1.48E-02 34 6.92E-02 21 1.96E-01
  Myc mediated apoptosis signaling 60 20 1.05E-02 19 8.71E-03 14 9.33E-03
Cellular stress and injury Endoplasmic reticulum stress pathway 18 7 6.03E-02 7 3.98E-02 4 1.73E-01
Disease-specific pathways Parkinson’s signaling 16 4 4.32E-01 4 3.61E-01 - -
Neurotransmitters and other nervous system signaling Cholecystokinin/gastrin-mediated signaling 106 24 2.59E-01 20 4.56E-01 - -
  1. bold: with statistical significance.